We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
Type
Public
HQ
San Diego, US
Founded
1995
Size (employees)
14 (est)+134%
Mast Therapeutics was founded in 1995 and is headquartered in San Diego, US
Report incorrect company information

Mast Therapeutics Office Locations

Mast Therapeutics has an office in San Diego
San Diego, US (HQ)
500 3611 Valley Centre Dr
Show all (1)
Report incorrect company information

Mast Therapeutics Financials and Metrics

Mast Therapeutics Financials

Mast Therapeutics's revenue was reported to be $128 k in FY, 2016
USD

Net income (Q1, 2018)

(26.8 m)

EBIT (Q1, 2018)

(32.1 m)

Market capitalization (22-Jun-2018)

371.8 m

Cash (31-Mar-2018)

22.1 m

EV

350 m
Mast Therapeutics's current market capitalization is $371.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

128 k

Revenue growth, %

(100%)

General and administrative expense

9.3 m11.1 m

R&D expense

12.9 m19.4 m28.3 m20.8 m18.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

45 k94 k

General and administrative expense

2.2 m2.3 m2.4 m2.5 m3.6 m2.4 m2.5 m2.8 m2.4 m2.1 m1.6 m5.1 m1.8 m

R&D expense

3.1 m4.3 m4.8 m5.4 m6 m7.7 m7.3 m7.9 m7.8 m5.1 m1.4 m4.2 m8.5 m

Operating expense total

5.3 m6.8 m7.2 m7.9 m9.7 m10.2 m9.8 m10.7 m10.2 m7.2 m5.8 m9.3 m32.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

25.7 m35.8 m23.1 m8.5 m22.1 m

Inventories

1.1 m1.1 m1.3 m903 k

Current Assets

45.5 m58.4 m42.3 m12.2 m97.9 m

PP&E

105.7 k188 k226 k99 k925 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

30.2 m29.8 m26.4 m26 m27.9 m21.2 m32.2 m23.5 m24.5 m20.5 m7.8 m61.1 m22.1 m

Current Assets

49.9 m50.6 m47.6 m44.1 m50.6 m44.8 m51.4 m38.2 m35.8 m28.3 m8.2 m63.7 m87.6 m

PP&E

115.1 k106.5 k186.3 k185.7 k248 k230 k250 k199 k171 k148 k88 k672 k837 k

Goodwill

3 m3 m3 m3 m3 m3 m3 m3 m3 m3 m3 m28.2 m27.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)(29.8 m)

Depreciation and Amortization

39.5 k85 k146 k99 k363 k

Accounts Payable

159 k

Cash From Operating Activities

(17.8 m)(24.6 m)(32.9 m)(37.3 m)(28.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(5.3 m)(6.4 m)(7.2 m)(7.9 m)(9.6 m)(10.2 m)(9.9 m)(11.2 m)(10.7 m)(8.2 m)(5.9 m)(26.8 m)

Depreciation and Amortization

10.1 k11.5 k22.5 k25.8 k30 k37 k38 k32 k30 k24 k11 k107 k

Accounts Payable

1.2 m1.2 m2.3 m2 m2.9 m2.5 m2.3 m1.5 m502 k(554 k)

Cash From Operating Activities

(9.7 m)
USDY, 2018

EV/EBIT

-10.9 x

EV/CFO

-36.2 x

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Mast Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information